Standard BioTools (LAB) AI Stock Analysis

• Market Cap: $534.79M
• Dividend Yield: N/A
• Average Volume (3M): 1.19M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: 13.17%
• EPS Growth: 64.50%
• Country: US
• Employees: 814
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 381,995,120
• 10 Day Avg. Volume: 1,139,387
• 30 Day Avg. Volume: 1,192,099
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.46
• Enterprise Value/Revenue: 1.61
• Enterprise Value/Gross Profit: 3.71
• Enterprise Value/Ebitda: -2.72
• 1Y Price Target: $1.55
• Price Target Upside: 10.71% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: $1.50 ▲(7.14% Upside)

The overall stock score is primarily impacted by the company's weak financial performance, characterized by declining revenues and negative profit margins. Technical analysis provides some neutral support, but poor valuation metrics further weigh down the score.

Positive Factors

Low Debt Levels

Low debt levels provide financial flexibility and reduce risk, allowing the company to navigate financial challenges without significant leverage-related constraints.

Revenue Streams

Diverse revenue streams from products and services provide stability and potential growth opportunities, mitigating risks associated with reliance on a single income source.

Strategic Partnerships

Partnerships enhance innovation and market reach, fostering collaborative research and potential product development, which can drive long-term growth.

Negative Factors

Declining Revenues

Declining revenues indicate potential loss of market share or demand, which can hinder the company's ability to invest in growth and innovation, affecting long-term prospects.

Negative Profit Margins

Negative profit margins reflect operational inefficiencies and financial strain, limiting the company's ability to reinvest in the business and sustain long-term growth.

Cash Flow Challenges

Cash flow challenges can restrict the company's ability to fund operations and strategic initiatives, potentially impacting its competitive position and financial health over time.

Standard BioTools Business Overview & Revenue Model

Company Description

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

How the Company Makes Money

Standard BioTools generates revenue through multiple key streams, primarily by selling its proprietary laboratory instruments, consumables, and software solutions to research institutions, pharmaceutical companies, and clinical laboratories. The company also benefits from ongoing service contracts and maintenance agreements for its equipment, which provide a steady revenue flow. Additionally, Standard BioTools engages in strategic partnerships with academic institutions and industry players, allowing for collaborative research efforts that can lead to innovative product development and expanded market reach. These partnerships often include licensing agreements, which can further enhance the company's revenue potential.

Standard BioTools Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenues and negative profit margins. Despite a low debt-to-equity ratio, profitability and cash flow are under pressure.

Income Statement

The income statement reveals a challenging financial situation with declining revenues and negative profit margins. The TTM data shows a revenue decline of 9.1%, and the net profit margin is significantly negative at -78.1%. Gross profit margin has decreased to 43.3% from 48.3% in the previous year. The company is struggling with profitability as indicated by negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.067, indicating low leverage, which is a positive aspect. However, the return on equity is negative at -26.2%, reflecting poor profitability. The equity ratio is not explicitly calculated, but the company maintains a strong equity position relative to its assets.

Cash Flow

Cash flow analysis highlights negative operating and free cash flows, with a free cash flow growth rate of -14.9% TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is above 1, suggesting that free cash flow exceeds net income, which is a positive sign.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	154.24M	174.43M	106.34M	97.95M	130.58M	138.14M
Gross Profit	66.84M	84.26M	50.45M	37.05M	69.37M	83.33M
EBITDA	-91.35M	-118.14M	-54.46M	-173.57M	-43.77M	-32.59M
Net Income	-120.50M	-138.88M	-74.66M	-190.10M	-59.24M	-53.02M
Balance Sheet
Total Assets	556.97M	612.34M	323.07M	390.31M	275.21M	324.76M
Cash, Cash Equivalents and Short-Term Investments	237.09M	292.87M	114.89M	165.78M	28.45M	68.52M
Total Debt	28.62M	33.00M	98.21M	102.66M	111.65M	95.38M
Total Liabilities	132.43M	140.62M	159.87M	471.78M	180.62M	185.71M
Stockholders Equity	424.54M	471.72M	163.20M	229.79M	94.60M	139.05M
Cash Flow
Free Cash Flow	-105.46M	-151.81M	-46.12M	-93.19M	-57.33M	-28.13M
Operating Cash Flow	-92.88M	-143.45M	-43.29M	-89.37M	-44.06M	-15.42M
Investing Cash Flow	36.97M	363.17M	20.24M	-88.13M	-11.95M	39.98M
Financing Cash Flow	-54.46M	-102.62M	-6.81M	230.76M	15.96M	20.86M

Standard BioTools Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Positive. The current price of 1.4 is above the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.31, and above the 200-day MA of 1.34, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 59.36 is Neutral, neither overbought nor oversold. The STOCH value of 75.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LAB.

Standard BioTools Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	63 Neutral	683.19M	-13.38	-4.57%	―	4.31%	69.57%
CSTL	59 Neutral	708.09M	-68.63	-2.08%	―	20.40%	-165.41%
MYGN	52 Neutral	722.96M	-1.81	-101.83%	―	3.83%	-137.31%
OPK	52 Neutral	1.15B	-5.81	-13.66%	―	-7.31%	29.84%
PSNL	52 Neutral	540.93M	-4.79	-47.85%	―	0.36%	22.13%
LAB	45 Neutral	$534.79M	―	-22.40%	―	13.17%	64.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Standard BioTools Corporate Events

Standard BioTools Announces Strategic Restructuring Plan

On August 28, 2025, Standard BioTools Inc. announced a strategic restructuring plan to consolidate its R&D capabilities from South San Francisco to its Singapore facility, aligning with its manufacturing operations. This move, aimed at enhancing operational efficiency and reducing costs, involves a reduction-in-force affecting U.S. employees and is expected to incur expenses of approximately $3.6 million, with potential for additional costs due to unforeseen events.

The most recent analyst rating on (LAB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Standard BioTools Announces SomaLogic Sale to Illumina

Standard BioTools reported its financial results for the second quarter of 2025, highlighting a total revenue of $42 million, with $21.8 million from continuing operations. The company announced the strategic sale of SomaLogic to Illumina for up to $425 million, expected to close in the first half of 2026, which will significantly bolster its cash reserves to at least $550 million. This move is part of a broader strategy to streamline operations and focus on profitability by 2026, despite challenges such as reduced U.S. academic spending and global capital constraints. The company is pausing its earnings calls temporarily to focus on operational adjustments.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.